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Abstract
Background: Brain metastases are common in patients with melanoma, and optimal management is not well
defined. As melanoma has traditionally been thought of as “radioresistant,” the role of whole brain radiation therapy
(WBRT) in particular is unclear. We conducted this retrospective study to identify prognostic factors for patients
treated with stereotactic radiosurgery (SRS) for melanoma brain metastases and to investigate the role of additional
up-front treatment with whole brain radiation therapy (WBRT).
Methods: We reviewed records of 147 patients who received SRS as part of initial management of their melanoma
brain metastases from January 2000 through June 2010. Overall survival (OS) and time to distant intracranial
progression were calculated using the Kaplan-Meier method. Prognostic factors were evaluated using the Cox
proportional hazards model.
Results: WBRT was employed with SRS in 27% of patients and as salvage in an additional 22%. Age at SRS>60 years
(hazard ratio [HR] 0.64, p=0.05), multiple brain metastases (HR 1.90, p=0.008), and omission of up-front WBRT (HR 2.24,
p=0.005) were associated with distant intracranial progression on multivariate analysis. Extensive extracranial
metastases (HR 1.86, p= 0.0006), Karnofsky Performance Status (KPS)≤ 80% (HR 1.58, p= 0.01), and multiple brain
metastases (HR 1.40, p=0.06) were associated with worse OS on univariate analysis. Extensive extracranial metastases
(HR 1.78, p =0.001) and KPS (HR 1.52, p= 0.02) remained significantly associated with OS on multivariate analysis.
In patients with absent or stable extracranial disease, multiple brain metastases were associated with worse OS
(multivariate HR 5.89, p= 0.004), and there was a trend toward an association with worse OS when up-front WBRT
was omitted (multivariate HR 2.56, p= 0.08).
Conclusions: Multiple brain metastases and omission of up-front WBRT (particularly in combination) are associated
with distant intracranial progression. Improvement in intracranial disease control may be especially important in the
subset of patients with absent or stable extracranial disease, where the competing risk of death from extracranial
disease is low. These results are hypothesis generating and require confirmation from ongoing randomized trials.
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Metastatic tumors from primary sites outside the central
nervous system (CNS) are the most frequent intracranial
neoplasms. Melanoma is among the primary tumors
with the highest propensity for metastasis to the brain
[1]. Up to half of patients with melanoma develop brain
metastases, and once brain metastases are diagnosed,
median survival time is estimated to range between 3.4
and 13.2 months [2,3]. For individual patients, survival
depends on a number of factors, and there has been
much effort, both with brain metastases in general and
with melanoma brain metastases specifically, to identify
the factors that prognosticate for overall survival (OS)
[4-11]. This information can be useful for patients and
for their physicians who base treatment decisions in part
on prognostic factor data.
Treatment options for patients with melanoma brain
metastases include whole brain radiation therapy (WBRT),
surgery, stereotactic radiosurgery (SRS), systemic therapy,
some combination of these treatments, and supportive
measures alone [3,12]. SRS has become increasingly
common, even for patients with multiple brain metasta-
ses [13-22], but some authors caution against the regu-
lar omission of up-front WBRT [20,22]. Randomized
data support adding WBRT to SRS for initial manage-
ment of patients with brain metastases (not specific to
patients with melanoma as the primary cancer) for the
improvement of intracranial disease control, but not
overall survival [23-25]. The translation of intracranial
disease control to overall survival depends on competing
risks from extracranial disease as well as the availability
and efficacy of salvage options, suggesting that the impact
of WBRT may differ depending on these factors. Data
from a randomized trial of SRS alone versus SRS and
WBRT specifically in patients with melanoma is not yet
available [26], and retrospective studies are vulnerable
to selection bias [13-18,27].
In this retrospective study of melanoma patients treated
with SRS for brain metastases, we sought to evaluate the
potential utility of WBRT, given the lack of randomized
evidence specific to this subpopulation, and to identify
prognostic factors associated with OS and distant intracra-
nial progression. Though we cannot eliminate selection
bias altogether in a retrospective study examining the
utility of WBRT, we sought to mitigate the effects of




This study was approved by the Dana-Farber/Harvard
Cancer Center Institutional Review Board.
We identified 243 consecutive patients with a histo-
logical diagnosis of melanoma who were treated with
SRS for brain metastases from January 2000 through
June 2010 at the Dana-Farber/Brigham & Women’s
Cancer Center (DF/BWCC) or the Beth Israel Deaconess
Medical Center (BIDMC). One patient was excluded due
to lack of follow-up data. Thirty-five patients in whom
SRS was performed only on a surgical resection cavity
were also excluded. An additional 65 patients were
excluded because SRS was performed only as salvage
therapy. As ap r i o r iintention-to-treat could not be
assigned retrospectively, salvage SRS was defined as
any SRS performed greater than 3 months from the
date of first treatment for brain metastases (i.e. the date
of WBRT or surgery when these treatments were used
p r i o rt oS R S )o ra n yS R Sp e r f o r m e df o rp r o g r e s s i o no f
intracranial disease (even if within 3 months of the first
treatment). We reviewed records of the remaining 147
patients who received SRS as the initial management of
their melanoma brain metastases. The follow-up schedule
was not uniform in all cases, but the typical approach was
to obtain brain magnetic resonance imaging (MRI) 6–8
weeks after SRS alone followed by MRI every 3 months
thereafter if stable and every three months after WBRT.
Stereotactic radiosurgical technique
At DF/BWCC, SRS was performed using the Novalis™
linear accelerator-based radiosurgery platform. Prior to
2009, all patients were immobilized with the use of a
fixed head frame. In 2009, conventional frame-based
radiosurgery was replaced by frameless delivery using
the thermoplastic BrainLAB cranial mask immobilization
system. At BIDMC, SRS was performed using the X-
Knife® linear accelerator-based radiosurgery platform or,
beginning in 2005, the Cyberknife® platform.
Statistical analysis
Distant intracranial progression was defined as the pres-
ence of a new enhancing lesion consistent with a brain
metastasis or leptomeningeal enhancement outside of
the SRS target volume on any MRI after the date of SRS.
Estimates of time to intracranial progression and OS
were calculated using the Kaplan-Meier method. Time
to distant intracranial progression was defined as the
interval from SRS to the date of first distant intracranial
progression (censored at the date of last MRI demon-
strating no evidence of progression). OS was defined as
the interval from SRS to the date of death (censored at
the date of last clinical follow-up). The effects of clinical
and demographic covariates on intracranial progression
and OS were estimated using a Cox proportional hazards
model. Variables with a p-value<0.1 on univariate analysis
were used to construct a multivariate model. (Age, as a
continuous variable, was included in the multivariate
model for OS regardless of significance on univariate
analysis, given that for people in general, age is the most
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used a significance level of 0.05 (two-sided) and a 95%
confidence interval (95% CI). Analyses were performed
using SAS (version 9.2) and R (version 3.0.3).
Clinical factors that were analyzed included patient
age, Karnofsky Performance Status (KPS), number of
brain metastases (one versus multiple), time from initial
diagnosis of melanoma to SRS, use of up-front WBRT,
the status of extracranial disease (absent or stable versus
progressive), and the extent of extracranial metastases
(limited versus extensive). In terms of extracranial dis-
ease status, “progressive” was defined as any evidence
of new or progressing systemic disease on restaging
computed tomography (CT) scan (by review of radiology
reports and physician notes) within the 3 months prior
to SRS. If no CT was available in the 3 months prior to
SRS, then any restaging CT performed in the month
following SRS was used. To define the extent of extra-
cranial metastases, each patient was assigned a number
between 0 and 6 based on evidence of any current (i.e. at
t h et i m eo fS R S )o rp a s tm e l a n o m am e t a s t a s e st ot h e
following 6 sites: liver, lung, adrenal glands, other
visceral organs, bone, or other distant site (e.g. lymph
nodes or subcutaneous tissue). For example, if a par-
ticular patient had metastases to lungs, liver, and distant
subcutaneous tissue, then the patient would be assigned
a “3”. The median number of extracranial body sites
affected by metastatic disease was used to dichotomize the
extent-of-extracranial-metastases variable into “limited
extracranial metastases” (less than or equal to the median
number of body sites affected by metastatic melanoma)
and “extensive extracranial metastases” (greater than the




The median follow-up time for survivors was 23 months.
The frequency of clinical covariates is shown in Table 1.
Median age was 60 years. Eighty patients (54%) had KPS
of 90% or 100%; 61 patients (41%) had KPS of 70% or
80%; and 6 patients (4%) had KPS of 50% or 60%.
Thirty-five patients (24%) had absent or stable extracra-
nial metastases, while 112 patients (76%) had progressive
extracranial disease. The median number of extracranial
sites affected by metastatic melanoma was 2. Eighty-six
patients (59%) had “limited extracranial metastases” (i.e.
≤ 2 sites affected by metastatic melanoma), and 61
patients (41%) had “extensive extracranial metastases”
(i.e. ≥ 3 extracranial sites affected by metastatic melanoma)
At DF/BWCC, 54% of patients were initially treated with
WBRT in addition to SRS (i.e. “up-front WBRT”), while
only 3% of patients had up-front WBRT at BIDMC.
An additional 13% of patients at DF/BWCC and 30% of
patients at BIDMC received salvage WBRT. Only 2 of 59
patients (3%) with one brain metastasis received up-front
WBRT, while 37 of 88 patients (42%) with multiple brain
metastases did so. The use of up-front WBRT was associ-
ated with treatment center (Fisher’s exact test: p <0.0001)
and multiple brain metastases (p <0.0001). The median
number of brain metastases for patients receiving WBRT
up front was 4 (IQR 3–5) while those treated with SRS
alone was 1 (IQR 1–2).
Intracranial progression
Fifty-six patients had distant failure prior to any local
failure (i.e. progression within the SRS treatment field);
20 had distant and local failure at the same time; and 27
people had local failure first (10 of these 27 people
went on to develop distant intracranial progression at
a later time). Therefore, distant intracranial progres-
sion occurred in a total of 86 patients (59%). Median
time to distant intracranial progression was 4.3 months.
Table 2 lists the results of Cox regression analysis for
time to distant intracranial progression. On multivariate
analysis, age>60 years (hazard ratio [HR] 0.64, p=0.05),
multiple brain metastases (HR 1.90, p=0.008), and
omission of up-front WBRT (HR 2.24, p=0.005) were
associated with distant intracranial progression. In
patients with multiple brain metastasis, median time
to distant intracranial progression was 2.0 months in
patients in whom WBRT was initially omitted (i.e. those
treated with SRS alone or SRS and surgery as initial
treatment), and 6.0 months in patients treated with
up-front WBRT (in addition to up-front SRS [and, in
some cases, up-front surgery as well]) (p=0.003). In
patients with a single brain metastasis, however, the
median time to distant intracranial progression was
approximately 5 months, both in patients treated with
up-front WBRT and in patients in whom WBRT was
initially omitted. Figure 1 shows the Kaplan-Meier
curves for distant intracranial progression by use of
up-front WBRT in the subset of 88 patients with
multiple brain metastases. In terms of local failure (i.e.
growth of the lesion[s] within the SRS treatment field), on
Cox univariate analysis, both WBRT (HR 2.56, p=0.02)
and diameter of largest brain metastasis (diameter >1 cm:
HR 2.70, p=0.03) were associated with local failure first
(i.e. local progression taking place prior to distant intra-
cranial progression), but WBRT was not significant on
multivariate analysis or when number of brain metasta-
ses was added to the model. Of the patients who did not
receive up-front WBRT and who subsequently failed,
42% received WBRTas salvage therapy.
Overall survival
Death occurred in 135 patients (92%), and median OS was
7.3 months. Table 3 lists the results of Cox regression
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ated with worse OS were extensive extracranial metastases
(HR 1.86, p=0.0006), multiple brain metastases (HR 1.40,
p=0.06), and KPS ≤ 80 (HR 1.58, p=0.01). Extensive
extracranial metastases and KPS remained significantly
associated with OS on multivariate analysis. When either
or both omission of up-front WBRT and multiple brain
metastases were included in the model, neither was sig-
nificant; similarly, when the OS analysis was performed
in the subgroup of patients with multiple brain metasta-
ses, omission of up-front WBRT was not significant.
The final multivariate model for OS in the general cohort
contains three variables: age (as a continuous variable; HR
0.99, p=0.37), extensive extracranial metastases (HR 1.78,
p=0.001), and KPS≤80 (HR 1.52, p=0.02). Median sur-
vival for patients with extensive extracranial metastases
and KPS≤80 was 3.8 months, compared to 10.8 months
in patients with limited extracranial metastases and KPS
90 or 100.
Subset analysis in patients with absent or stable
extracranial disease
We repeated the Cox regression analyses in the subset
of 35 patients with absent or stable extracranial disease.
Multiple brain metastases (HR 4.64 [95% CI 1.54 – 13.94],
p=0.006) and omission of up-front WBRT (HR 3.14
[95% CI 1.02-9.68, p= 0.05) were associated with distant
intracranial progression in the multivariate model. The
final multivariate model for OS in this subset contained
age (as a continous variable; HR 1.02, p=0.24), multiple
brain metastases (HR 5.89 [95% CI 1.79 – 19.43], p =
0.004), and omission of up-front WBRT (HR 2.56 [95%
CI 0.91 – 7.23], p=0.08). Therefore, there was a trend
toward worse OS with omission of up-front WBRT.




60 (51 – 68) 28 – 92
Time from primary Melanoma
to Brain Metastasis (months)
39 (17 – 69) 0 – 347
Diameter of largest brain
Metasasis (mm)





Extent of extracranial metastases:*
0 12 (8%)
1 Limited 28 (19%) 86 (59%)
2 46 (31%)
3 35 (24%)





Present and stable 23 (16%)
Present and progressive 112 (76%)
Number of brain metastases:
1 59 (40%)
2 – 3 53 (36%)
>3( 4 –10) 35 (24%)
Karnofsky performance status:
50 – 60 6 (4%)
70 – 80 61 (41%)
90 – 100 80 (54%)
Initial treatment:
DF/BWCC BIDMC
SRS Alone 29 (43%) 66 (84%)
SRS+ WBRT 23 (34%) 0 (0%)
SRS+ Surgery 2 (3%) 11 (14%)
SRS+ Surgery+ WBRT 14 (21%) 2 (3%)
Whole-brain radiation therapy:
DF/BWCC BIDMC
Up-Front (with SRS) 37 (54%) 2 (3%)
As Salvage Therapy 9 (13%) 24 (30%)
Never 22 (32%) 53 (67%)





Table 1 Patient characteristics and clinical covariates
(Continued)
Melanoma-GPA score:




Abbreviations: IQR interquartile range, DF/BWCC Dana-Farber/Brigham &
Women’s Cancer Center, BIDMC Beth Israel Deaconess Medical Center,
SRS stereotactic radiosurgery, WBRT whole brain radiation therapy,
Melanoma-GPA melanoma-specific Graded Prognostic Assessment for
brain metastases.
*To define the “extent of extracranial metastases”, each patient was assigned a
number between 0 and 6 based on evidence of melanoma metastases to the
following 6 sites: liver, lung, adrenal glands, other visceral organs, bone, or
other distant site (e.g. lymph nodes or subcutaneous tissue). The median
number of extracranial body sites affected by metastatic melanoma is 2.
“Limited extracranial metastases” was defined as ≤2 extracranial body sites
affected by metastatic melanoma. “Extensive extracranial metastases” was
defined as≥ 3 extracranial body sites affected by metastatic melanoma.
†Systemic Treatment with SRS = systemic treatment given after SRS and before
disease progression.
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was put in the Cox model in place of the up-front-WBRT
variable, there was no such trend. Figure 2 shows the
Kaplan-Meier curves for OS by number of brain metasta-
ses in the subset of 35 patients with absent/stable extracra-
nial disease (Figure 2B) and in the subset of 112 patients
with progressive extracranial disease (Figure 2A). Given
that extent of extracranial metastases (limited vs. exten-
sive) – not the status of extracranial disease (absent/stable
vs. progressive) – was associated with OS in the entire co-
hort, a subset analysis was also performed in patients with
limited extracranial disease. When both number of brain
metastases and up-front WBRT were entered into the
Cox regression model for OS in the 86 patients with
limited extracranial disease, there was a trend toward
an association with worse OS for multiple brain metas-
tases, but WBRT was not significant.
Discussion
In our series of patients with melanoma brain metastases
treated with SRS, multiple brain metastases and omission
of up-front WBRT were associated with distant intracra-
nial progression. Whether or not the factors associated
with freedom from distant intracranial progression would
also be expected to improve OS depends partly on the
issue of competing risk, that is, whether intracranial dis-
ease or extracranial disease is the main driver of mortality.
If mortality is driven by intracranial disease, then factors
that improve intracranial disease control, such as fewer
brain metastases and the initial use of WBRT with SRS,
would also be expected to improve OS. On the other
hand, if extracranial disease is driving mortality, then
extracranial disease burden (e.g. the extent of extracranial
metastases) and status (e.g. whether the extracranial dis-
ease is stable or progressing) would be expected to affect
mortality, while number of brain metastases and WBRT
would not. Indeed, in our study, none of the factors that
improved freedom from distant intracranial progression
(or freedom from local failure) was in our final model for
OS. Extracranial disease, more so than intracranial disease
factors or progression, appears to drive mortality in the
overall cohort.
In our analysis of the subset of patients with absent or
stable extracranial disease, the factors associated with
improved survival were those related to intracranial
disease. Specifically, of the three factors associated with
distant intracranial progression in the entire cohort,
one (i.e. multiple brain metastases) was also associated
with poor OS in the subset analysis (p=0.004), and
another (i.e. omission of up-front WBRT) demonstrated
a trend toward such an association (p=0.08). Extracra-
nial disease status may, therefore, modify the effect of
intracranial disease burden (and control) on OS, such
that the number of brain metastases (and the use of
up-front WBRT) is prognostic for survival in patients
with absent or stable extracranial metastases, but not in
patients with progressive extracranial disease.
Recently we argued that for certain cancers, such as
lung cancer, the presence versus absence of extracranial
Table 2 Model selection for time to distant intracranial progression
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age at SRS >60 years 0.66 0.43 – 1.01 0.05 0.64 0.41 – 0.99 0.05
Time from primary to brain met <39 mo. 1.16 0.76 – 1.77 0.50
Extensive ECM (vs. Limited)* 1.20 0.77 – 1.89 0.43
Progressive ECD (vs. absent/stable) 1.15 0.70 – 1.87 0.58
Number of brain metastases >1 1.45 0.93 – 2.24 0.10 1.90 1.18 – 3.06 0.008
Diameter of brain metastasis >1 cm 0.85 0.55 – 1.30 0.44
KPS 50 – 80 (vs. 90 or 100) 0.90 0.58 – 1.41 0.65
Omission of up-front WBRT 1.54 0.91 – 2.60 0.09 2.24 1.27 – 3.94 0.005
Abbreviations: HR hazard ratio, CI confidence interval, SRS stereotactic radiosurgery, Met metastasis, ECM extracranial metastases, ECD extracranial disease,
KPS Karnofsky Performance Status, WBRT whole brain radiation therapy.
*See Materials and Methods section and Table 1 for definitions of “extensive” and “limited” extracranial metastases.
Figure 1 Kaplan-Meier curves for distant intracranial progression
by use of WBRT. (Only the 88 patients with greater than 1 brain
metastasis are included in the figure). (Logrank: p=0.003). Abbreviations:
WBRT=whole brain radiation therapy; SRS=stereotactic radiosurgery.
Dyer et al. Radiation Oncology 2014, 9:143 Page 5 of 9
http://www.ro-journal.com/content/9/1/143Table 3 Model selection for overall survival
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age at SRS (in years, continuous)* 1.00 0.98 – 1.01 0.46 0.99 0.98 – 1.01 0.37
Age at SRS >60 years 0.94 0.67 – 1.32 0.71
Time from primary to brain met <39 mo. 1.11 0.79 – 1.55 0.56
Extensive ECM (vs. Limited)
† 1.86 1.31 – 2.64 0.0006 1.78 1.25 – 2.53 0.001
Progressive ECD (vs. absent/stable) 1.22 0.82 – 1.82 0.32
Number of brain metastases >1 1.40 0.99 – 1.98 0.06
Diameter of brain metastasis >1 cm 1.24 0.89 – 1.75 0.21
KPS 50 – 80 (vs. 90 or 100) 1.58 1.12 – 2.21 0.01 1.52 1.08 – 2.15 0.02
Omission of up-front WBRT 0.96 0.66 – 1.41 0.85
Abbreviations: HR hazard ratio, CI confidence interval, SRS stereotactic radiosurgery, Met metastasis, ECM extracranial metastases, ECD extracranial disease,
KPS Karnofsky Performance Status, WBRT whole brain radiation therapy.
*Age (as a continuous variable) was included in multivariate models for overall survival regardless of significance on univariate analysis.
†See Materials and Methods section and Table 1 for definitions of extensive and limited extracranial metastases.
Figure 2 Kaplan-Meier curves for overall survival by number of brain metastases, separated by extracranial disease status. (A: Subset of
patients with progressive extracranial disease. B: Subset of patients with absent or stable extracranial disease). (One patient with progressive
extracranial disease in the multiple brain metastasis group was censored at 75 months, and one patient with absent/stable disease in the single
brain metastasis group was censored at 102 months [not shown in figure]). (Logrank for 112 patients with progressive extracranial disease: p=0.59.
Logrank for 35 patients with absent/stable extracranial disease: p=0.01). Abbreviations: SRS=stereotactic radiosurgery.
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extracranial disease burden, whereas a more granular
approach may be necessary for other cancers [28]. In
our series of 51 patients treated with SRS for breast
cancer brain metastases, extracranial disease status,
measured as absent or stable versus progressive (as
opposed to absent versus present), was our most robust
prognostic factor for OS and added pertinent additional
information to the established prognostic index, the
Graded Prognostic Assessment (GPA) [28]. For patients
with melanoma, where 92% and 76% of the patients in
our cohort had present and progressive extracranial dis-
ease, respectively, an even more granular measure may
be necessary. Indeed the “extent of extracranial metasta-
ses” variable that we defined for this study may better
capture the overall burden of extracranial disease in
patients with metastatic melanoma. Even this variable is
an imperfect proxy for overall disease burden, however.
Other groups have also shown the importance of extra-
cranial disease as a prognostic factor for OS in patients
with melanoma brain metastases, and some did so by
measuring lactate dehydrogenase (LDH) level, which
may also capture the extent of extracranial disease in a
more granular fashion [9-11,15,17]. Adding some surro-
gate for extracranial disease burden to existing prognos-
tic indices that do not already include such a factor may
improve these indices.
The data regarding the use of WBRT for patients with
melanoma are mixed, with some authors arguing that
melanoma is a radioresistant tumor with limited benefit
from non-SRS radiation treatments [14]. Some studies
have shown no benefit of WBRT for melanoma brain
metastases [13-15,27,29], while others suggest WBRT
may improve intracranial disease control [17] or survival
[18]. Several studies acknowledge that the absence of an
observed effect of WBRT on intracranial disease control
or survival might be due to selection bias. While we are
not able to eliminate unmeasurable selection bias in this
retrospective study, we hopefully diminished its effects
with respect to WBRT by including patients from two
treatment centers with different institutional practices.
One center frequently performed both SRS and WBRT
as part of initial management of melanoma brain metas-
tases (particularly in those with more than one brain
metastasis), while the other rarely did so. Even with this
attempt to diminish selection bias in our study, the use
of WBRT was as strongly associated with multiple brain
metastases as it was with treatment center. Our results
do, however, suggest that WBRT added to SRS improves
freedom from distant intracranial progression (especially
in patients with multiple brain metastases), providing
some evidence that melanoma is not as uniformly radio-
resistant (and that the utility of WBRT in melanoma
is not as limited) as some have argued. Whether the
reduction in distant intracranial failure is clinically
important in the overall course of the disease is in
question, but the effect of WBRT in reducing failure is
less so, given our data.
One limitation of our study is the degree to which we
are able to address the question of whether improved
intracranial control matters. Whether improvements in
intracranial control translate to a more meaningful clin-
ical benefit (such as overall survival) depends not only
on competing risk, but also on the efficacy of salvage op-
tions. We could not directly compare up-front WBRT to
salvage WBRT, as only 42% of eligible patients received
salvage WBRT. Our data does not provide direct evi-
dence to either support or refute any claim on this issue,
but the trend toward better OS with the initial use of
WBRT in patients with absent or stable extracranial dis-
ease may suggest imperfect salvage options. Further-
more, while our institutional practice has been to obtain
surveillance MRI every 3 months, this could not be
standardized in a retrospective study and the potential
impacts of more frequent monitoring on salvage options
and efficacy is unknown.
Multiple randomized trials of WBRT and SRS versus
SRS alone in patients with brain metastases from various
primary cancers (mostly lung and breast cancers) sug-
gest that WBRT does not improve OS [23-25]. Yet in
certain primary cancers, especially in those that are
more likely to have progressive intracranial disease as a
source of mortality, the improvements in intracranial
control caused by WBRT may theoretically contribute to
a survival benefit. Such cancers may act more aggres-
sively in the CNS or have a more limited risk of extra-
cranial disease progression. Whether melanoma fits into
this category is currently unknown. Conversely, if extra-
cranial disease progression is the primary driver of mortal-
ity, then WBRT may have a very limited role in addition
to focal therapies, as prophylaxis against distant brain me-
tastases may not be clinically relevant in such a scenario.
Additionally, more frequent MRI surveillance may
increase the efficacy of salvage therapy, obviating the need
for upfront WBRT. A randomized, phase III trial of local
therapy (neurosurgical resection and/or SRS) with or with-
out WBRT for patients with melanoma brain metastases
is currently being conducted by the Australia and New
Zealand Melanoma Trials Group and the Trans Tasman
Radiation Oncology Group [26]. In this trial, rando-
mization is stratified by extracranial disease status. Such
randomized trials that stratify by extracranial disease
status may have the best potential for confirming our
findings and the findings from other retrospective studies.
Conclusions
In summary, we identified multiple brain metastases and
the omission of up-front WBRT (particularly in those
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with distant intracranial progression after SRS. The ef-
fect of these factors on OS was modified by extracranial
disease status, such that multiple brain metastases and
(to a degree that could be characterized as a trend)
omission of up-front WBRT were associated with worse
OS in patients with absent or stable extracranial disease,
but not in those with progressive extracranial disease.
The data also confirm the significance of KPS for OS
and suggest that extracranial disease burden (as mea-
sured by the number of extracranial body sites affected
by melanoma metastases) may be an important factor
for OS in the general population of patients undergoing
SRS for melanoma brain metastases. As the ability to
control systemic disease in patients with metastatic
melanoma improves, the contribution of intracranial
disease burden and control in helping to determine OS
may increase.
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